Can CTC levels predict progression of hormone-sensitive prostate cancer?

Posted on July 15, 2011 by Sitemaster

The levels of circulating tumor cells (CTCs) — as evaluated using Cellsearch technology — is becoming accepted as a prognostic marker for disease progression among men with  metastatic castration-resistant prostate cancer (mCRPC), and may even be accepted soon as a surrogate marker for prostate cancer-specific mortality in clinical trials of new agents. … READ MORE …

Filed under: Living with Prostate Cancer, Management | Tagged: , , , , , | 2 Comments »

CTCs from patients with CRPC have specialized markers

Posted on June 28, 2011 by Sitemaster

A team of researchers at Duke University have shown that most men with castration-resistant prostate cancer (mCRPC) express multiple epithelial proteins in their circulating T cells (CTCs). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: , | Leave a Comment »

Survival and CTC data from the abiraterone acterate pivotal trial

Posted on June 5, 2011 by Sitemaster

As we have previously reported, the latest analysis of survival data from the pivotal Phase III trial of abiraterone acetate + predisone has shown a slight improvement in the survival benefit for patients treated with abiraterone (Zytiga™). … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , | Leave a Comment »

Could new test for CTSCs help prostate cancer patients?

Posted on April 6, 2011 by Sitemaster

To date there has only been one test available for assay of levels of circulating tumor cells (CTCs) in men with prostate cancer: the CellSearch test made by Veridex. This test is widely recognized to come with a variety of challenges, and the potential of CTCs in assessing risk for progression of prostate cancer (and other cancers) has therefore been limited. … READ MORE …

Filed under: Living with Prostate Cancer, Management | Tagged: , , , , , | Leave a Comment »

Two negatives don’t make a positive in patients with CRPC

Posted on December 7, 2010 by Sitemaster

Data from a small Phase II trial of cilengitide suggest that it  has minimal clinical effect in the treatment of men with non-metastatic, castration-resistant prostate cancer (CRPC). They also suggest that levels of circulating T-cells (CTCs) are of limited utility in monitoring the progression of this patient group. … READ MORE …

Filed under: Drugs in development | Tagged: , , , , | Leave a Comment »

The prognostic value of CTCs in low-volume prostate cancer

Posted on October 11, 2010 by Sitemaster

Circulating tumor cell (CTC) levels have clearly been shown to have relevance to the prognosis of men with metastatic, castration-resistant prostate cancer, but we still know little about their potential importance in men with early stage disease. … READ MORE …

Filed under: Management, Risk | Tagged: , , | 11 Comments »

CTCs as a prognostic tool in advanced prostate cancer

Posted on July 15, 2009 by Sitemaster

Circulating tumor cells (CTCs) have been approved for marketing by the US Food and Drug Administration as a useful prognostic tool for the management of patients with advanced prostate cancer. … READ MORE …

Filed under: Management | Tagged: , , , | Leave a Comment »

Prostate cancer news reports: Sunday, May 24, 2009

Posted on May 24, 2009 by Sitemaster

Today’s news reports deal with such matters as:

  • Advances in radical prostatectomy
  • Variations in mutation in androgen-resistant patients
  • Data from a Phase I/II trial of AT-101
  • The link between CTC level and response to therapy with abiraterone … READ MORE …

Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: , , , , , , | Leave a Comment »

The Monday news update: March 2, 2009

Posted on March 2, 2009 by Sitemaster

New reports today address:

  • Positive surgical margins: RALP vs. RRP
  • Circulating tumor cells levels and survival of castration-resistant prostate cancer patients
  • Patient preference and management of post-surgical incontinence … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | 4 Comments »

Tuesday’s news reports: February 16, 2009

Posted on February 17, 2009 by Sitemaster

For the engineers, the scientists, and other technically minded readers, there are a number of very “dense” scientific news reports today. … READ MORE …

Filed under: Diagnosis, Management, Treatment | Tagged: , , , , , | 2 Comments »

Can CTC counts be used as surrogate endpoints in clinical trials?

Posted on February 11, 2009 by Sitemaster

Intermediate or surrogate endpoints for survival can shorten timelines for drug approval. A paper just published on line in Lancet Oncology aimed to assess the value of circulating tumor cell (CTC) counts as a prognostic factor for survival. … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , | Leave a Comment »

Thursday’s other news reports: February 5, 2009

Posted on February 5, 2009 by Sitemaster

There are a number of additional reports in today’s news (above and beyond the reports on risks associated with disseminated tumor cells and a new review of PSA and PCA3 testing as aids to diagnosis): … READ MORE …

Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: , , , , , | Leave a Comment »

The prostate cancer news update: Friday, October 10

Posted on October 10, 2008 by Sitemaster

Today’s news includes information about:

  • A review of the risk associated with testosterone therapy in men with low testosterone levels
  • Issues related to stress and coping among couples dealing with prostate cancer
  • The pivotal trial leading to approval of circulating T-cell counts as a means to evaluate treatment of men with very late-stage prostate cancer … READ MORE …

Filed under: Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: , , , , , | Leave a Comment »

Prostate cancer news update: Tuesday, August 26

Posted on August 26, 2008 by Sitemaster

There are several interesting news items today, as follows:

  • Ethnic variation in the performance of PSA and PSA density as markers for risk of prostate cancer
  • Potential underuse of active surveillance in eligible patients
  • Application of active surveillance in a 40-patient case series
  • The potential to eliminate the need for a urethral (Foley) catheter post-surgery
  • Circulating tumor cell levels as a predictor for response to androgen deprivation therapy … READ MORE …

Filed under: Diagnosis, Management, Treatment, Uncategorized | Tagged: , , , , , , , , , , , , , | 1 Comment »

Follow

Get every new post delivered to your Inbox.

Join 867 other followers